person · Reporting owner
Toledano Miranda Jayne
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | June 25, 2021 | June 29, 2021 |
| Entera Bio Ltd.ENTX · Entity 5464 | Director · Chief Executive Officer | August 07, 2026 | August 07, 2026 |
| Journey Medical CorpDERM · Entity 6273 | Director | July 01, 2026 | July 02, 2026 |
| NEXGEL, INC.NXGL · Entity 8400 | Director | August 17, 2023 | August 21, 2023 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | EVP-Corporate Development | September 16, 2016 | October 05, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date June 25, 2021 · Filed June 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 Par ValueSEC Table I · non-derivative | Direct | 1,791,549 |
Reported balance
After 2021-06-25 transaction · row 1
1 source rowRow 1 · 2021-06-25 · Other · Acquired 1,791,549 · Balance 1,791,549 F1: The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 | Direct | 50,000 |
Reported balance
After 2021-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-25 · Grant · Acquired 50,000 · Balance 50,000 F2: The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement.
F2: The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021.
Entera Bio Ltd.
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-06 | Direct | 500,000 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 500,000 · Balance 500,000 F1: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 · Expires 2036-08-07 | Direct | 200,000 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Grant · Acquired 200,000 · Balance 200,000 F2: Represents a grant of options to purchase ordinary shares. This grant of options was originally approved by the Board on July 15, 2022, subject to (i) approval by the Company's shareholders, which was obtained on September 7, 2022, (ii) the occurrence of a Triggering Event (as defined and specified in Ms. Toledano's employment agreement), which was satisfied upon the Company obtaining the necessary resources to fund its Phase 3 trial through the consummation of the Company's July 2026 financing transaction, and (iii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a four-year period that commenced on August 7, 2026, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
F2: Represents a grant of options to purchase ordinary shares. This grant of options was originally approved by the Board on July 15, 2022, subject to (i) approval by the Company's shareholders, which was obtained on September 7, 2022, (ii) the occurrence of a Triggering Event (as defined and specified in Ms. Toledano's employment agreement), which was satisfied upon the Company obtaining the necessary resources to fund its Phase 3 trial through the consummation of the Company's July 2026 financing transaction, and (iii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a four-year period that commenced on August 7, 2026, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
Journey Medical Corp
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 168,618 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 50,000 · Balance 168,618 F1: On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031. F2: Includes restricted stock units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031.
F2: Includes restricted stock units, which vest over various time periods.
NEXGEL, INC.
Report date August 17, 2023 · Filed August 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2033-08-17 | Direct | 15,000 |
Reported balance
After 2023-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-17 · Grant · Acquired 15,000 · Balance 15,000 F1: Represents stock options granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended, for past services as a member of the Issuer's Board of Directors. The total number of shares vested as of August 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended, for past services as a member of the Issuer's Board of Directors. The total number of shares vested as of August 17, 2023.
Sorrento Therapeutics, Inc.
Report date September 16, 2016 · Filed October 05, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.93 · Expires 2026-09-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2016-09-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 32,500 of the stock options vest on September 16, 2017 and 1/48 of the remaining options shall vest following each one month period of service thereafter, subject to the reporting person's continued service to the Company through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 32,500 of the stock options vest on September 16, 2017 and 1/48 of the remaining options shall vest following each one month period of service thereafter, subject to the reporting person's continued service to the Company through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 20:19 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001178913-26-003950 · zk2635792.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 200,000 shares Expires 2036-08-07 F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was originally approved by the Board on July 15, 2022, subject to (i) approval by the Company's shareholders, which was obtained on September 7, 2022, (ii) the occurrence of a Triggering Event (as defined and specified in Ms. Toledano's employment agreement), which was satisfied upon the Company obtaining the necessary resources to fund its Phase 3 trial through the consummation of the Company's July 2026 financing transaction, and (iii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a four-year period that commenced on August 7, 2026, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| August 07, 2026 Filed Aug 7, 2026 20:19 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001178913-26-003950 · zk2635792.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares Expires 2036-05-06 F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:05 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 72,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003508 · zk2635690.xml · nonDerivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 847,135 F2 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2026. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:05 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 347,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003508 · zk2635690.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,142 F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2025 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:07 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080320 · tm2619538-3_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,618 F1 · shares: On July 1, 2026, the reporting person was granted 50,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 16,666 shares on July 1, 2029, 16,667 shares on July 1, 2030 and 16,667 shares on July 1, 2031. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:05 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078817 · tm2619089-3_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,618 F1 · shares: On June 25, 2026, the reporting person was granted 10,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 10,000 shares on June 25, 2027. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 11:01 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 11,000 | $1.81 | $19,912.20 |
DisclosureSEC source: 0001178913-25-004125 · ownership.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,575 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:16 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-075266 · tm2522819-3_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,618 F1 · shares: On August 5, 2025, the reporting person was granted 20,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in accordance with the following schedule: 6,667 shares on August 5, 2028, 6,667 shares on August 5, 2029 and 6,666 shares on August 5, 2030. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:37 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001178913-25-002414 · zk2533456.xml · derivative · entry 3 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares Expires 2035-04-28 F3 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:37 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 43,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-002414 · zk2533456.xml · nonDerivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,575 F2 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2025. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 1, 2025. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:37 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 136,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-25-002414 · zk2533456.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,715 F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025. Read SEC document |
| June 25, 2025 Filed Jul 8, 2025 01:50 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 7,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-066240 · tm2520050-5_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,618 F1 · shares: On June 25, 2025, the reporting person was granted 7,173 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in full on June 25, 2026. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:30 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001178913-24-002391 · zk2431765.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares Expires 2034-04-19 F2 · derivative.exercise_date: This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 20:30 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantOrdinary Shares, par value NIS 0.0000769 per share | 124,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-24-002391 · zk2431765.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,873 F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:45 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, $0.0001 par value | 9,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-078970 · tm2419199-2_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,445 F1 · shares: On July 8, 2024, the reporting person was granted 9,728 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 8, 2025. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 13:27 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseWarrants (right to buy) · Derivative | 23,952 | $0.13 Strike: $1.00 | $2,994.00 |
DisclosureSEC source: 0001178913-23-003971 · zk2330699.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,952 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares Expires 2028-12-22 F1 · derivative.exercise_price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 13:27 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 23,952 | $0.71 | $17,005.92 |
DisclosureSEC source: 0001178913-23-003971 · zk2330699.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,752 F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 21:02 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001178913-23-003156 · zk2330299.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 350,000 shares Expires 2033-04-24 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 24, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:34 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001493152-23-029652 · ownership.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's 2019 Long-Term Incentive Plan, as amended, for past services as a member of the Issuer's Board of Directors. The total number of shares vested as of August 17, 2023. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083831 · tm2321950-4_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 units of which will vest on July 1, 2024. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:05 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 30,000 | $1.01 | $30,300.00 |
DisclosureSEC source: 0001178913-23-001348 · zk2329512.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 14:13 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 50,000 | $0.53 | $26,585.00 |
DisclosureSEC source: 0001178913-22-003988 · zk2228743.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001178913-22-003372 · zk2227078.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 600,000 shares Expires 2032-07-15 F2 · derivative.exercise_date: This grant of options was approved by the Board on July 15, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on July 15, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001178913-22-003372 · zk2227078.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 11, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on May 16, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 13:35 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082287 · tm2221508-3_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 21:04 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 6,800 | $2.79 | $18,971.32 |
DisclosureSEC source: 0001178913-22-000165 · zk2227078.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 20:49 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042282 · tm2211324-11_4.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:12 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000095 · zk2227047.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:12 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000095 · zk2227047.xml · derivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| December 27, 2021 Filed Jan 3, 2022 21:45 UTC | NEXGEL, INC. NXGL · Entity 8400 | GrantWarrant to Purchase Common Stock · Derivative | 1,819 | $0.01 Strike: $5.50 | $18.19 |
DisclosureSEC source: 0001104659-22-000437 · tm221361-4_4seq1.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 Underlying: Common Stock · 1,819 shares Expires 2026-12-26 F1 · kind: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's underwritten public offering which closed on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Jan 3, 2022 21:45 UTC | NEXGEL, INC. NXGL · Entity 8400 | PurchaseCommon Stock | 1,819 | $5.49 | $9,986.31 |
DisclosureSEC source: 0001104659-22-000437 · tm221361-4_4seq1.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 F1 · acquired: The Reporting Person acquired the shares of common stock and warrant to purchase common stock reported on this Form 4 in connection with the Issuer's underwritten public offering which closed on December 27, 2021. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 18:31 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001686530-21-000006 · edgar.xml · derivative · entry 2 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, $.0001 Par Value · 50,000 shares Expires not disclosed F2 · derivative.exercise_date: The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021. F2 · derivative.expiration_date: The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 18:31 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | OtherCommon Stock, $.0001 Par Value | 1,791,549 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001686530-21-000006 · edgar.xml · nonDerivative · entry 1 Toledano Miranda Jayne · CIK 0001686530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791,549 F1 · shares: The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement. F1 · price: The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.